You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Extended Dosing

Showing 1 - 25 of 9,035
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy Trial in Toronto (Risperidone, Olanzapine)

Recruiting
  • Schizophrenia and Related Disorders
  • +3 more
  • Toronto, Ontario, Canada
    Centre for Addiction and Mental Health
Jul 20, 2022

Severe Aplastic Anemia (SAA) Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Eltrombopag)

Active, not recruiting
Has Results
  • Severe Aplastic Anemia (SAA)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
May 12, 2021

Severe Hemophilia A Without Inhibitor Trial in Pathum Wan (Extended half-life FVIII concentrates with PK-guided dosing, standard

Completed
  • Severe Hemophilia A Without Inhibitor
  • Extended half-life FVIII concentrates with PK-guided dosing
  • standard half-life FVIII concentrates with weight-based dosing
  • Pathum Wan, Bangkok, Thailand
    Pediatric department, Faculty of medicine, Chulalongkorn Univers
Jul 19, 2022

Kidney Transplant Trial in Philadelphia (Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within

Completed
  • Kidney Transplant
  • Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant
  • Philadelphia, Pennsylvania
    Temple University Hospital
Feb 10, 2022

Metastatic Cancer Trial in Chicago, Madison (Nivolumab Standard, Pembrolizumab Standard, Nivolumab Extended)

Recruiting
  • Metastatic Cancer
  • Nivolumab Standard
  • +3 more
  • Chicago, Illinois
  • +1 more
Dec 23, 2021

Natalizumab Extended Interval Dosing in a French Cohort

Completed
  • Multiple Sclerosis, Relapsing-Remitting
  • Natalizumab Injection [Tysabri]
  • Bobigny, France
  • +4 more
Mar 8, 2022

Relapsing Remitting Multiple Sclerosis Trial in Netherlands (Personalized extended interval dosing of natalizumab, Standard

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Personalized extended interval dosing of natalizumab
  • Standard interval dosing
  • Almelo, Netherlands
  • +23 more
Sep 22, 2021

Primary Hyperoxaluria Type 1 (PH1) Trial in Worldwide (Placebo, Lumasiran)

Active, not recruiting
Has Results
  • Primary Hyperoxaluria Type 1 (PH1)
  • San Diego, California
  • +15 more
Mar 4, 2022

Gram-Negative Infections Trial in Cairo (Piperacillin/Tazobactam Continuous infusion, Piperacillin/Tazobactam Intermittent

Completed
  • Gram-Negative Infections
  • Piperacillin/Tazobactam Continuous infusion
  • Piperacillin/Tazobactam Intermittent infusion
  • Cairo, Egypt
    Cairo University Hospitals
May 18, 2021

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial in Mineola, New York, Toronto (DPX-Survivac,

Completed
  • Epithelial Ovarian Cancer
  • +2 more
  • DPX-Survivac
  • +2 more
  • Mineola, New York
  • +2 more
Jun 16, 2021

s in Wet Age-related Macular Degeneration Which Have Never

Active, not recruiting
  • Wet Age-related Macular Degeneration
  • Aflibercept (Eylea, BAY86-5321)
  • Multiple Locations, Argentina
  • +16 more
Jan 16, 2023

Papillomavirus Infections Trial in Worldwide (9vHPV vaccine)

Active, not recruiting
  • Papillomavirus Infections
  • 9vHPV vaccine
  • Daly City, California
  • +29 more
May 18, 2022

Heart Transplant Rejection, Graft Failure, Compliance, Patient Trial in Dallas (Envarsus)

Active, not recruiting
  • Heart Transplant Rejection
  • +2 more
  • Dallas, Texas
    Baylor University Medical Center
Jul 29, 2020

Healthy Trial in Cairo (Bladogra, Myrbetriq (first dosing), Myrbetriq (second dosing))

Completed
  • Healthy
  • Cairo, Egypt
    Genuine Research Center GRC
Jul 20, 2020

Attention-Deficit/Hyperactivity Disorder Trial in Canada, United States (extended-release guanfacine HCl (SPD503), ,

Completed
Has Results
  • Attention-Deficit/Hyperactivity Disorder
  • extended-release guanfacine hydrochloride (SPD503)
  • +2 more
  • Little Rock, Arkansas
  • +45 more
May 14, 2021

Chronic Pain Trial in Toronto (Extended Release Opioid Formulation, Shortened Intervals, Extended Release Opioid Formulation,

Withdrawn
  • Chronic Pain
  • Extended Release Opioid Formulation, Shortened Intervals
  • +2 more
  • Toronto, Ontario, Canada
    University Health Network
Mar 25, 2020

Attention-Deficit/Hyperactivity Disorder Trial in United States (Extended-release Guanfacine Hydrochloride, Placebo)

Completed
Has Results
  • Attention-Deficit/Hyperactivity Disorder
  • Extended-release Guanfacine Hydrochloride
  • Placebo
  • Dothan, Alabama
  • +53 more
Jun 25, 2021

Ulcerative Colitis Trial in Boston (CP-101, CP-101 + Placebo)

Not yet recruiting
  • Ulcerative Colitis
  • Boston, Massachusetts
    Brigham and Women's Hospital
May 9, 2023

ADHD, ADHD Trial in Irvine (Methylphenidate Hydrochloride Extended Release Capsules, Placebo)

Completed
Has Results
  • Attention Deficit Hyperactivity Disorder
  • ADHD
  • Methylphenidate Hydrochloride Extended Release Capsule
  • Placebo
  • Irvine, California
    University of California, Irvine/Child Development Center
Nov 16, 2022

Opioid Use Disorder Trial (Buprenorphine Extended-Release Injection)

Not yet recruiting
  • Opioid Use Disorder
  • Buprenorphine Extended-Release Injection
  • (no location specified)
Feb 2, 2023

Bioequivalence, Diabetes, Type 2 Trial in San Pedro Garza García (Sitagliptin/Metformin HCl 100/1000 mg extended release

Completed
  • Bioequivalence
  • Diabetes Mellitus, Type 2
  • Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
  • San Pedro Garza García, Nuevo León, Mexico
    Avant Santé Research Center S.A. de C.V.
Nov 8, 2023

Bioequivalence, Diabetes, Type 2 Trial in San Pedro Garza García (Sitagliptin/Metformin HCl 50/500 mg extended release

Completed
  • Bioequivalence
  • Diabetes Mellitus, Type 2
  • Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet
  • San Pedro Garza García, Nuevo León, Mexico
    Avant Santé Research Center S.A. de C.V.
Nov 8, 2023

Immunosuppression Trial in Charleston (Tacrolimus Extended Release Capsule, Mycophenolate mofetil, Prednisone)

Completed
Has Results
  • Immunosuppression
  • Tacrolimus Extended Release Capsule
  • +3 more
  • Charleston, South Carolina
    Medical University of South Carolina
Dec 10, 2019

Smoking Cessation Trial in Kansas City (Bupropion)

Not yet recruiting
  • Smoking Cessation
  • Kansas City, Missouri
    University of Kansas Medical Center
Feb 7, 2023

Smouldering Myeloma Trial in Worldwide (Carfilzomib, Dexamethasone, Lenalidomide)

Recruiting
  • Smouldering Myeloma
  • Brno, Czechia
  • +15 more
Mar 22, 2022